Webinar Alert! Assessing the Use of Non-Human Primates in Translational Research Today Register Today!

Developing a Robust qPCR Assay for Detecting Lentiviral Vector Sequences in Peripheral Blood Mononuclear Cells (PBMCs)

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Developing a Robust qPCR Assay for Detecting Lentiviral Vector Sequences in Peripheral Blood Mononuclear Cells (PBMCs)

CELL & GENE | RNA | BIOLOGICS

Quantifying Safety: Precision Biodistribution for Advanced Therapies.

What is a suitable Lower Limit of Quantification (LLOQ) for a validated LVV qPCR assay in PBMCs?
A well-optimized assay is designed to achieve a limit of quantification that is sufficiently sensitive to meet regulatory requirements for monitoring vector biodistribution and persistence during preclinical safety studies. This level of performance requires meticulous primer and probe design coupled with robust DNA extraction methods to maximize yield and purity from the PBMC matrix.
How do you control for background signal from endogenous retroviral sequences in the human genome?
Specificity is a primary consideration. We design primer and probe sets that target unique sequences within the lentiviral vector construct that have no homology with known human endogenous retroviruses (HERVs). This often involves targeting regions like the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE) or specific elements of the transgene cassette. Each assay undergoes rigorous in silico analysis and wet-lab specificity testing against human genomic DNA to confirm the absence of cross-reactivity.
What sample processing considerations are key for isolating high-quality DNA from PBMCs for qPCR analysis?
Consistent and high-quality DNA isolation is a prerequisite for reliable data. Key considerations include the immediate processing or appropriate cryopreservation of whole blood to maintain PBMC integrity, the selection of an isolation method (e.g., column-based vs. magnetic bead) validated for high recovery and purity, and the accurate quantification of the resulting genomic DNA. We standardize these pre-analytical variables to minimize variability between samples and ensure data integrity.
How does Franklin Biolabs approach primer and probe design to ensure specificity for the integrated lentiviral vector provirus?
Our approach is multi-faceted. We begin by identifying multiple candidate target regions exclusive to the vector backbone or payload. We then use bioinformatics tools to screen these sequences against relevant genomic databases to eliminate any potential for non-target amplification. Finally, we empirically test the top candidate primer/probe sets for performance characteristics, including amplification efficiency, specificity, and sensitivity, before selecting the optimal set for full GxP validation.

For cell therapies utilizing lentiviral vectors (LVVs), quantifying vector copy number in peripheral blood mononuclear cells (PBMCs) is a primary objective for IND-enabling safety packages. A robust, GxP-validated quantitative PCR (qPCR) assay provides the definitive data on systemic vector exposure, persistence, and biodistribution required by regulatory agencies. Developing such an assay demands a deep understanding of vector biology, matrix-specific challenges, and the stringent requirements of GxP compliance to support an accelerated 18-24 month IND timeline.

<a href=”

The Regulatory Requirement for Lentiviral Vector Biodistribution Data

Regulatory guidance for ex vivo gene therapies requires a thorough assessment of vector biodistribution. Because transduced cells are administered systemically, PBMCs serve as a key surrogate tissue for evaluating the presence and persistence of vector sequences in circulation. This analysis informs the overall safety profile, helping to characterize proliferation of vector-containing cells or unexpected biodistribution patterns.

Our bioanalytical team develops and validates custom qPCR assays that form a core component of the data package supporting regulatory submissions. Since our brand launch in 2024, we have maintained the 100% IND success rate established by our core team since 2019, demonstrating our capability in generating submission-ready data.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

A digital rendering of a DNA double helix on a dark blue background with floating particles.

A stylized, 3D rendering of a DNA double helix in light blue and white, set against a soft-focus, light gray background.

Technical Strategy for GxP-Compliant qPCR Assay Development

A successful qPCR assay for LVV sequences in PBMCs is built on a systematic, phase-appropriate validation strategy. Our process is designed to produce reliable, reproducible data fit for regulatory scrutiny.

  • Target Selection and Specificity: We design assays targeting unique regions of the LVV construct, ensuring no cross-reactivity with the host genome.

  • Reference Standard Qualification: We generate and thoroughly characterize plasmid or genomic DNA reference standards to ensure accurate quantification of vector copy numbers.

  • Matrix Effect Mitigation: We optimize DNA extraction protocols specifically for PBMCs to remove PCR inhibitors and maximize recovery, ensuring assay performance is not compromised by the biological matrix.

  • GxP Validation: The assay undergoes a full validation protocol assessing key parameters according to regulatory expectations.

Validation Parameter Franklin Biolabs Approach
Specificity Confirmed against non-transduced human genomic DNA.
Sensitivity (LLOQ) Established as the lowest point on the standard curve with acceptable precision and accuracy.
Accuracy & Precision Evaluated at multiple concentration levels across multiple runs and analysts.
Stability Assessed for extracted DNA under intended short-term and long-term storage conditions.

Integrating Advanced Methodologies for Comprehensive Safety Assessment

The scientific principles driving the development of advanced analytical tools, such as the ITR-Seq method for identifying genome-wide editing sites for AAV vectors (PMID: 32183699), inform our broader bioanalytical strategy. This work underscores the industry-wide need for developing highly sensitive and specific assays to fully characterize vector behavior in vivo. While qPCR is the established method for LVV biodistribution, we apply that same forward-thinking rigor to our assay design, anticipating future regulatory questions. Our >100,000 sq ft facility provides the specialized laboratory infrastructure required to execute these complex bioanalytical studies under a unified quality system.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities